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Abstract
Background: Microcell-mediated chromosome transfer (MMCT) is a technique by which a chromosome(s) is moved 
from donor to recipient cells by microcell fusion. Polyethylene glycol (PEG) has conventionally been used as a fusogen, 
and has been very successful in various genetic studies. However, PEG is not applicable for all types of recipient cells, 
because of its cell type-dependent toxicity. The cytotoxicity of PEG limits the yield of microcell hybrids to low level (10-
6 to 10-5 per recipient cells). To harness the full potential of MMCT, a less toxic and more efficient fusion protocol that 
can be easily manipulated needs to be developed.
Results: Microcell donor CHO cells carrying a human artificial chromosome (HAC) were transfected with genes 
encoding hemagglutinin (H) and fusion (F) proteins of an attenuated Measles Virus (MV) Edmonston strain. Mixed 
culture of the CHO transfectants and MV infection-competent human fibrosarcoma cells (HT1080) formed 
multinucleated syncytia, suggesting the functional expression of the MV-H/F in the CHO cells. Microcells were 
prepared and applied to HT1080 cells, human immortalized mesenchymal stem cells (hiMSC), and primary fibroblasts. 
Drug-resistant cells appeared after selection in culture with Blasticidin targeted against the tagged selection marker 
gene on the HAC. The fusion efficiency was determined by counting the total number of stable clones obtained in 
each experiment. Retention of the HAC in the microcell hybrids was confirmed by FISH analyses. The three recipient 
cell lines displayed distinct fusion efficiencies that depended on the cell-surface expression level of CD46, which acts as 
a receptor for MV. In HT1080 and hiMSC, the maximum efficiency observed was 50 and 100 times greater than that 
using conventional PEG fusion, respectively. However, the low efficiency of PEG-induced fusion with HFL1 was not 
improved by the MV fusogen.
Conclusions: Ectopic expression of MV envelope proteins provides an efficient recipient cell-oriented MMCT protocol, 
facilitating extensive applications for studies of gene function and genetic corrections.
Background
Microcell fusion is a method which enables the transfer
of a single mammalian chromosome or its fragment from
donor to recipient cells. This method consists of five
essential steps: 1) micronucleation of donor cells; 2) enu-
cleation of the micronucleated cells; 3) isolation of micro-
cells; 4) fusion of microcells with recipient cells; and 5)
selection of viable microcell hybrid clones. Microcell-
mediated chromosome transfer (MMCT) offers several
advantages for the transfer of genetic material between
mammalian cells. Thus, megabase-sized stretches of an
intact chromosome can be moved, which tend to be sta-
ble and freely segregating in recipient cells [1]. MMCT to
patient-derived cells, followed by functional complemen-
tation assays, has been used for the genetic mapping and
identification of genes responsible for hereditary reces-
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sive disorders and for tumor suppressor genes [2-5].
Other fields have taken advantage of MMCT for address-
ing genomic instability, genomic imprinting, chromatin
modification, and structural and spatial organization of
the genome [1,6-9]. Transfer of human chromosome frag-
ments or artificially engineered chromosomes into
embryonic stem cells has also successfully produced tran-
schromosomic (Tc) animals [10,11]. These Tc animals
have been used as sources of therapeutics and as models
of human disorders such as Down's syndrome [2,12,13].
MMCT has also been applied to construction and manip-
ulation of artificial chromosome vectors for potential
human gene therapies [14,15]. MMCT has thus paved the
way for the use of mammalian chromosomes as gene
delivery vectors.
The most commonly used reagent for microcell fusion
is high molecular weight polyethylene glycol (PEG) [16].
Since the establishment of standard method in the 1980s,
the MMCT has been achieved with a specific class of
recipient cells, for which the introduction of considerable
changes in the fusion protocol was not necessary. How-
ever, little is known about the fusion mechanism of PEG.
PEG may cause the redistribution of intramembrane mol-
ecules within the plasma membrane. This ability of PEG
has been attributed to the ordering of water induced by a
high concentration of polymer [17]. As well as inducing
cell fusion, the PEG treatment concomitantly results in
extensive cell damage and loss of cell viability because of
the induced cytotoxicity [18]. Sensitivity to the PEG cyto-
toxicity is known to be cell type-dependent and is regu-
lated by the lipid composition of the cell membrane
[19,20]. Consistent with these data, the success of micro-
cell fusion by PEG seems to depend on the particular
combination of donor and recipient cells. Characteriza-
tion and engineering of the lipid composition of cell
membranes in order to avoid the PEG cytotoxicity is an
intriguing but da unting task [21]. T herefore, to exploit
novel applications of the MMCT, a more efficient, less
toxic and more easily manipulated fusion protocol than
PEG treatment needs to be developed.
One well-documented naturally occurring membrane
fusion event is that which occurs during the infection of
host cells by enveloped viruses. The measles virus (MV),
which causes the acute contagious disease of measles, has
an envelope protein complex that is used for both virus
attachment and membrane fusion [22]. The complex is
composed of two integral membrane proteins, the
hemagglutinin (H) and fusion (F) proteins. MV-H is the
transmembrane glycoprotein responsible for the interac-
tion of the virus with its cellular receptors. Two receptors
have been identified for the live attenuated Edmonston B
vaccine strain of MV (MV-Edm): the ubiquitously
expressed regulator of complement activation CD46 and
the lymphocyte-specific protein of the immunoglobulin
(Ig) superfamily, SLAM. The H protein mediates attach-
ment to either one of these cell surface receptors, and sig-
nals to the F protein to trigger membrane fusion. Infected
MV propagates both by virus release and reinfection, and
by cell-cell fusion. Virus-induced cell-cell fusion plays an
important role in the propagation and pathogenicity of
MV. MV-Edm has been shown to be selectively oncolytic
[23]. This effect is due to the fact that CD46 is upregu-
lated in tumor cells, thereby allowing MV-Edm to selec-
tively target and destroy tumor cells through this receptor
[24]. Furthermore, MV-Edm has been retargeted by engi-
neering the H protein to efficiently enter tumor cells via
alternative cellular receptors [25,26]. These previous
studies prompted us to test the idea that transduction of
genes encoding the H and F proteins into non-human
donor cells may lead to the production of fusogenic
microcells (Figure 1).
In this study, we tested the feasibility of using the MV
viral fusion machinery as an alternative to PEG for micro-
cell fusion. An expression vector encoding the MV-H and
F genes was transfected into a CHO cell line which car-
ries an artificial human chromosome (HAC) tagged with
a drug-resistant selection marker. Functional expression
of the transfected MV-H/F plasmids was confirmed by
syncytium formation in a mixed culture of the engineered
CHO cells with CD46-expressing HT1080 (fibrosarcoma)
cells. Microcells were prepared from the donor cells and
overlaid on HT1080, hiMSC (human immortalized mes-
enchymal stem cells), or HFL-1 (primary fibroblasts,
derived from fetal lung) recipient cells. Drug-resistant
colonies were obtained by selection culture and introduc-
tion of the HAC was confirmed by FISH analysis. The
efficiency of microcell fusion with HT1080 or hiMSC
using the MV fusogen was higher than that using PEG by
an order of magnitude whereas the low efficiency of PEG-
induced fusion with HFL1 was not improved by the MV
fusogen. Difference in the fusion efficiency by the MV
fusogen may be explained by the expression level of the
CD46 receptor on these recipient cells. Potential exten-
sion of the host tropism of fusogenic microcells is also
discussed.
Results
Introduction of the MV-F/H genes confers human cell-
directed fusion ability on CHO cells
As the first step towards microcell fusion using an MV
fusogen, we transfected expression cassettes encoding the
MV-H and -F proteins, and the Neo/DsRed plasmid, into
CHO(HAC) cells, which carry a HAC engineered from
human chromosome 21 [14]. In the course of construc-
tion, the HAC was tagged with a Blasticidin-resistant
(Bsr) gene and GFP. After transfection, the cells were cul-
tured in medium containing the antibiotic G418. The
G418-resistant cell population was recovered and desig-Katoh et al. BMC Biotechnology 2010, 10:37
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nated as CHO4H6.1M. Most of them expressed both GFP
and DsRed fluorescences (Figure 2a, b, c). It is known that
transfection of MV-H/F into human cells induce syncy-
t i u m  f o r m a t i o n  b y  h o m o fu s i o n  ( F i g u r e  2 e ) .  U n l i k e  t h e
case with MV-H/F transfected human cells, no syncytium
was observed during propagation of the CHO4H6.1M
cells (Figure 2a). The absence of syncytium formation was
consistent with the prediction that the fusion machinery
of the human specific-ecotropic MV does not function in
rodent cells. The surface expression of the H protein was
assessed by flowcytometry analysis. About one third of
the cells showed slight expression of the H protein (addi-
Figure 1 Rationale for microcell fusion using an MV fusogen. Donor CHO cells carry a human artificial chromosome (HAC) tagged with blastcidin-
resistant (Bsr) and GFP gene. The CHO cells are transfected with plasmids encoding the MV-Fusion (MV-F) and Hemagglutinin (H) proteins and selec-
tion marker (Neo/DsRed). Microcells are prepared from the G418-resistant CHO donors and gave to recipient human cells. They are commonly coated 
with MV fusogen but contain different chromosomes. The donor-derived chromosome within the microcell is donated to the recipient cells by mi-
crocell fusion, which is mediated by interaction of the MV fusogen and the CD46 receptor presented on the surface of recipient cells. (a) The bsr-
tagged HAC is rescued in mycrocell-hybrid by selection culture with Blasticidin. (b, c) On the other hand, introduction of the MV-H/F-tagged chromo-
some into recipient cells results in de novo synthesis of H/F proteins, leading to cell death caused by syncytium formation with the surrounding cells.
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tional file 1). It is generally expected that co-transfection
of linearlized plasmids are concatenated and integrated
together in the same chromosomal locus. Although the
concomitant expression of H and F was not directly
tested, a part of H protein expressing cells may also
express F protein.
We then tested the functional expression of H and F on
the cell surface. The CHO4H6.1M cells were co-cultured
with the human tumor cell line HT1080. After culture for
24 h, a multinucleated syncytium was observed and fur-
ther expanded (Figure 2f, g, h). Syncytia contained fluo-
rescence-positive and -negative nuclei that were
supposed to be derived from CHO and HT1080 cells,
respectively (Figure 2h). The occurrence of heterofusion,
and the absence of homofusion, suggested that although
the transfected MV-H/F proteins did not induce fusion in
the CHO cells, they were functionally expressed on the
CHO cell surface and could mediate fusion with human
cells.
The genetically engineered CHO cells produce fusogenic 
microcells
The ability of the CHO4H6.1M cells to function as donor
cells for microcell fusion was then tested. Microcells were
prepared from donor cells (~8 × 106) that expressed
DsRed and/or GFP (Figure 2a, b, c). These fluorescent
microcells (~8 × 105) were overlaid on 2 × 106 of HT1080
cells. Following 24 h incubation, weak fluorescence was
detected in a few recipient cells (Figure 3a), while most of
fluorescent microcells were retained as distinct particles.
Fluorescence in recipient cells was explained by either
Figure 2 Genetically engineered CHO cells can fuse with human cells. G418-resistant CHO cells (a) expressed the GFP (b) and/or the fluorescent 
marker DsRed (c). An equal number of the CHO cells (a) and HT1080 cells (d) were mixed, and photographed 3 days later (f, g, h). Similar to the MV-F/
H-transfected HT1080 cells (e), large multinucleated syncytia were observed (f). Syncytia made by heterofusion of CHO and HT1080 expressed GFP 
and DsRed fluorescence (g, h). The panels a, b, c and f, g, h show the same cell field, respectively. Scale bar, 10 μm. Photographs were taken under 
phase contrast (a,d,e,f) or fluorescence (b,c,g,h) microscopic conditions.Katoh et al. BMC Biotechnology 2010, 10:37
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transmission of the fluorescent protein from the micro-
cells or de novo synthesis in microcell hybrids. To con-
firm that the donor chromosome was transferred, the
cultures were expanded and treated with Blasticidin
which selects for cells carrying tagged HAC. A total of 80
drug-resistant colonies were detected following Blastici-
din selection. Selected colonies were picked up and prop-
agated for the following analysis. Unlike the case with
MV-H/F transfected human cells, no syncytium was
observed during propagation of the Blasticidin-resistant
clones.
FISH analysis was performed with the GFP expressing
cells for the detection of the HAC transfer (Figure 4).
Alphoid satellite probe derived from human chromosome
21 hybridized with endogenous chromsomes 21 and 13,
due to their sequence similarity [14]. In addition to these
endogenous chromosomes, the probe detected a
minichromosome, which is not present in parental
HT1080 cells (data not shown). Since the HAC was con-
structed by deleting almost all sequences from long and
short arm of the chromosome 21, it retains alphoid satel-
lite as substantial contents [14]. The estimated size of the
HAC is less than 10 Mb, which corresponds to 1/5 of the
original human chromosome 21. In comparison to the
endogenous chromosome 21, the size of the minichromo-
some matched to the prediction. Obvious change in the
karyotype of the host cells was not detected. These
results demonstrated the introduction of the HAC by
microcell fusion without disturbance of the host chromo-
somes.
It was noted that the colonies expressed GFP but not
DsRed (Figure 3b). A possible explanation as to why the
DsRed-expressing cells carrying HAC were not detected
is that a microcell hybrid which received the donor chro-
mosome tagged by DsRed/neo together with MV-H/F
genes could not survive because of homofusion or fusion
between surrounding cells. To test the elimination of the
neo gene associated with the DsRed gene, Blasticidin-
resistant clones were assessed for the sensitivity to G418
(additional file 2). All the clones tested were sensitive to
G418. These results indicated that stable microcell
hybrids were obtained by excluding the DsRed/neo-
tagged donor chromosomes. These data proved that
chromosome transfer was successfully achieved by
microcell fusion via an MV fusogen.
The MV fusogen is more efficient than PEG for microcell 
hybrid production
We next compared the efficiency of microcell fusion by
MV fusogen with that by PEG. For this purpose, different
amount of microcells were applied to the fixed number of
recipient HT1080 cells. From 5 × 107 of CHO4H6.1M
cells, ~5 × 106 of microcells were obtained. These micro-
Figure 3 Genetically engineered CHO cells can produce fusogenic microcells. (a) Microcells were prepared from the MV-F/H-transfected CHO 
cells and placed on HT1080 cells. Photographs were taken after 24 h. A few recipient cells emitting fluorescence were observed. (b) HT1080 cells that 
had been in contact with the microcells were selected for 14 days with Blasticidin and drug-resistant colonies were photographed. These cells ex-
pressed GFP but not DsRed, suggesting retention of the HAC and elimination of MV-F/H-tagged host chromosomes. Photographs were taken under 
phase contrast (left) or fluorescence (center and right) microscopic conditions. Scale bar, 10 μm.Katoh et al. BMC Biotechnology 2010, 10:37
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cells were aliquoted in five fractions with the ratio of
1,2,4,6,11, and applied to a fixed number (2 × 106) of
recipient cells. As a control, the conventional fusion
experiment using PEG was performed with the parental
HAC donor cell line CHOkkpqG4. Microcell fusion was
determined as the number of drug-resistant colonies fol-
lowing selection culture with Blasticidin (Figure 5). The
fusion efficiency by MV fusogen was consistently, and at
most 10 times, higher than that by PEG (Table 1).
Whereas fusion induced by PEG was gradually increased
in a microcell dose-dependent manner, fusion induced by
the MV fusogen did not show dose dependency. Input
over threshold amount of microcells with MV fusogen
seemed to reduce the appearance of microcell hybrids.
Efficiency of microcell fusion via the MV fusogen differs 
with different recipient cells
We next determined whether the relatively high microcell
fusion efficiency observed using the MV fusogen and
HT1080 cells at optimal conditions could also be
observed with other cell types. We therefore compared
the fusion efficiency of the MV-fusion system using
HT1080 with that using a mesenchymal stem cell line
hiMSC and primary fibroblast cells HFL-1. A fixed num-
ber of microcells was applied to different numbers of
recipient cells. After selection culture for 2 weeks, the
number of drug-resistant colonies was counted (Figure
6a). Irrespective of the number of recipient cells, MV-
fusion consistently induced more resistant colonies than
PEG fusion in the HT1080 cell cultures. Although the
colony number obtained by MV-fusion in hiMSC cells
was approximately half of that in HT1080 cells, the
hiMSC were also responsive to MV fusion. In contrast,
difference in an order of magnitude was not observed
between MV- and PEG-induced resistant colonies using
the HFL-1 cells. The PEG-induced fusion efficiency using
HFL-1 cells was quite low compared to the other cell lines
and this low level of fusion was not overcome using the
MV fusogen.
In HT1080 and hiMSC, it was noted that MV fusion
induced resistant colonies in small numbers of recipient
cells in which no colonies were induced by PEG fusion.
Fusion efficiency defined as frequency of drug resistant-
colony formation per recipient cells scored highest (~10-
4), when small number of recipient cells (2 × 104) were
used. In HT1080 and hiMSC, the maximum efficiency
was 50 and 100 times greater than that using conven-
tional PEG fusion, respectively.
For drug-resistant cells, FISH analysis was performed
for the detection of transferred HACs (Figure 7). In addi-
tion to the endogenous chromosomes 21 and 13, the
alphoid satellite probe detected a minichromosome,
which is not present in parental HT1080, hiMSC, and
HFL-1 cells. In comparison to the endogenous chromo-
some 21, the size of the minichromosomes matched to
the prediction. In HFL-1, the alphoid probe detected a
pair of endogenous chromosomes 21 and 13, whereas in
HT1080 and hiMSC, the probe detected a single chromo-
some 21. While HFL-1 is primary cells, HT1080 and
hiMSC were immortalized by the transformation [27].
Aberrant chromosome number in HT1080 and hiMSC
may be explained by the transformation. The result
obtained by the PEG fusion (data not shown) was consis-
tent with that of the MV fusion. These results demon-
strated that the HAC was transferred to the recipient cells
Figure 5 The MV fusogen is more efficient than PEG for microcell 
hybrid production. Microcells collected from 24 flasks (~5 × 106) were 
fractionated into 5 dosing amounts (2 × 105, 4 × 105, 8 × 105, 1 × 106, 2 
× 106) and added to (MV), or fused with (PEG), 2 × 106 of HT1080 cells 
in a 60-mm dish. On the following day, fused cells were plated onto 
two 100-mm dishes. Following selection culture for 14 days, drug-re-
sistant colonies were stained with Giemsa and photographed.
Figure 4 Detection of chromosome transfer from the microcell to 
the donor cell. Recipient cells exposed to the microcells, and selected 
by Blasticidin treatment, were analyzed by fluorescence in situ hybrid-
ization to detect cells containing the transferred HAC. The HAC is de-
lineated using an alphoid satellite probe derived from human 
chromosome 21, and is shown in red (arrow). The alphoid satellite 
probe detects endogenous chromosomes 13 and 21 (arrowhead), in 
addition to the HAC, due to their sequence similarity.Katoh et al. BMC Biotechnology 2010, 10:37
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by microcell fusion without disturbance of the host chro-
mosomes.
Efficiency of microcell fusion may depend on the surface 
density of the CD46 receptor
MV is known to be a potent and specific oncolytic agent
that causes cytopathic effects due to extensive syncytium
formation. A previous study reported that the extent of
intercellular fusion in MV-infected human cells including
HT1080, was determined by the surface density of CD46
[28]. These data suggested that the extent of microcell
f u s i o n  m a y  a l s o  b e  a f f e c t e d  b y  t h e  s u r f a c e  d e n s i t y  o f
CD46. Therefore, we measured the surface density of
CD46 in the three cell lines using flow cytometry. The
Table 1: Yield of drug-resistant microcell hybrids by using MV fusogen and PEG
Amount of applied microcells Colony number1
MV PEG
2 × 105 51 5
4 × 105 86 6
8 × 105 94 15
1 × 106 75 13
2 × 106 60 22
1. Number of Blasticidin-resistant colonies obtained from 2 × 106 of HT1080 cells.
Figure 6 The efficiency of microcell fusion correlated with the surface density of CD46 in recipient cells. (a)A given number of microcells (~8 
× 105) were applied to different numbers of recipient cells and fused using MV or PEG. Abundant microcell hybrids, assessed as the number of drug-
resistant colonies, were obtained using HT1080 and hiMSC cells. In contrast, few microcell hybrids were obtained using HFL-1 cells, irrespective of the 
fusogen used. (b) The expression level of CD46 on the cells was analyzed with flow cytometry by staining with FITC-conjugated anti-CD46 antibody 
(black peak) or an isotype control (white peak with solid line). No stained control was showed by white peak with dotted line. The numbers on the x 
and y axes represent fluorescence intensity and count of event, respectively. CD46 expression is indicated by the number within the graph which is 
the ratio of the mean fluorescence index of the black:white peaks.Katoh et al. BMC Biotechnology 2010, 10:37
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surface density of CD46 was quantified and expressed as
the ratio of the mean fluorescence index of anti-CD46
antibody-stained and isotype control-stained cells. The
HT1080, hiMSC, and HFL-1 cells showed high, moder-
ate, and low levels of CD46 surface expression, respec-
tively (Figure 6b). A correlation was noted between fusion
efficiency and expression level of CD46. These results is
consistent with the previous report of intercellular fusion
in MV-infected human cells that cell fusion was minimal
at low receptor densities but increased significantly above
a threshold density of the receptor [28]. Therefore, mea-
surement of the surface density of CD46 is a useful crite-
rion for prediction of the ability of the MV fusogen to
induce microcell fusion in recipient cells.
Discussion
We aimed to determine whether microcell fusion could
be achieved using an MV fusogen. We showed that intro-
duction of genes encoding MV envelope proteins enables
rodent cells to produce fusogenic microcells that effi-
ciently transmit donor chromosomes to recipient human
cells expressing a high level of CD46 (Figure 1). This
method has several advantages over the conventional
PEG-fusion method for chromosome transfer. First,
microcell hybrids can be obtained from a low number of
recipients, even from recipients that are too low in num-
ber for hybrids to be obtained by PEG-fusion, as long as
the recipients express the CD46 receptor over a threshold
density. Second, the procedure for microcell fusion is
extremely simple. Thus the formation of microcell
hybrids requires only the addition of prepared microcells
to recipient cells. This ease of application, which avoids
the laborious tasks of handling a highly viscous PEG solu-
tion and performing repeated washout steps, may
improve the reproducibility of microcell fusion. We
obtained abundant microcell hybrids using MV-fusion
even using donor cells that should have heterogeneity in
copy number of the harbored MV-F/H expression plas-
mids. Further improvement in the fusion efficiency can
be expected by clonal selection of donor cells with a high
level of MV-F/H expression.
Application of microcells over a threshold amount
inversely reduced the appearance of drug-resistant colo-
nies. In principle, the collected microcells are composed
of a heterogeneous population and the nature of the con-
tained chromosome is not uniform. Hence, a microcell
containing HAC is expected to yield drug-resistant colo-
nies. In contrast, a microcell containing the MV-F/H-
tagged donor chromosome can potentially induce sec-
ondary fusion between the microcell hybrid and the sur-
rounding recipient cells, which ultimately reduces the
survival of microcell hybrids carrying the HAC. Applica-
tion of lower numbers of microcells may help to obviate
the negative effects that occur due to carry-over of the
genes encoding the MV-H/F proteins.
The next issue for microcell fusion via an MV fusogen
is whether the tropism for recipient cells can be altered
from the default CD46 receptor to arbitrary receptors.
Engineering of viral tropism has been pursued for many
gene therapy-based strategies [29-31]. An MV-Edm-
reverse genetics system has allowed the design and con-
struction of recombinant MVs that are better suited for
oncolytic applications. Retargeting of MV has been
achieved by the addition of specificity domains to the
extracellular (carboxyl) H-protein terminus. Thus, the
addition of EGF or IGF1 to the H protein efficiently retar-
geted MV to CD46-negative rodent cells expressing the
human EGF or IGF1 receptor, and caused extensive syn-
Figure 7 Detection of transferred HAC in microcell hybrids by FISH. The transferred HAC (arrow) is delineated by fluorescence in situ hybridiza-
tion using an alphoid satellite probe derived from human chromosome 21. The alphoid satellite probe (red) detects endogenous chromosomes 13 
and 21(arrowheads), in addition to the HAC, due to their sequence similarity. Results from HT1080, hiMSC, or HFL-1 cells were placed on left, center, 
and right, respectively.Katoh et al. BMC Biotechnology 2010, 10:37
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cytium formation [32]. Furthermore, the addition of sin-
gle chain antibody fragments to the H protein also
efficiently retargeted MV to the EGF receptor, myeloma
surface antigen CD38, or urokinase receptor [25,26,33].
These results suggest that chimeric H proteins containing
an additional protein domain are functionally displayed
on the surface of transduced cells. Thus these chimeric H
proteins sustain the ability to interact with the targeted
receptor, and can proceed to membrane fusion by coop-
erating with the F protein. Therefore, modification of the
H protein potentially enables retargeting of fusogenic
microcells to recipient cells of interest.
Conclusions
The MV-fusogen procedure for microcell fusion that has
b e e n  d e m o n s t r a t e d  i n  t h i s  s t u d y ,  n o t  o n l y  f a c i l i t a t e s
microcell fusion but also facilitates future manipulation
of the cell targeting of microcells, by exploitation of pre-
viously established genetic engineering of the MV-H pro-
tein.
Methods
Cell culture
HT1080, and hiMSC cells were grown in Dulbecco's
modified Eagle's medium (Sigma) supplemented with
10% fetal bovine serum (BioWest). HFL-1, obtained from
the Riken cell bank, was grown in Ham's F12 medium
(Sigma) supplemented with 15% fetal bovine serum. HAC
donor CHO cells were grown in Ham's F-12 medium sup-
plemented with 10% fetal bovine serum.
MV envelope protein expression plasmids and transfection
Construction of the measles H protein expression plas-
mid pTNH6-H was previously described [20]. The plas-
mid pCAG-T7-F encodes the F protein of the
Edmonston-B strain under the control of CAG promoter
(Nakamura, unpublished). The DsRed/neo expression
plasmid, pDsRed-Monomer-N1, was purchased from
Clontech. Plasmids were linearized by restriction diges-
tion with PvuI (NEB) before transfection. HAC donor
CHO cells (8 × 104/well in 24-well plate (Nunc))were co-
transfected with 0.3 μg each of pTNH6-H and pCAG-T7-
F, and 0.25 μg of pDsRed-Monomer-N1 using cationic
lipid (Lipofectamine 2000; Invitrogen). At 24 h after
transfection, the cells were re-plated at low density and
selected for 14 days with 800 μg/ml of G418 (Nacalai).
Drug-resistant cells were recovered as a mixed popula-
tion.
HT1080 cells (2 × 106/6 cm dish) were co-transfected
with 0.4 μg each of pTNH6-H and pCAG-T7-F using cat-
ionic lipid (Lipofectamine 2000). After culture for 6 h,
syncytium formation was tested under microscope.
Co-culture assay
Equal numbers (1 × 105) of G418-resistant CHO cells and
HT1080 cells were plated in a 60-mm dish (Beckton
Dickinson) and cultured for a period of 3 days and syncy-
tium formation was determined microscopically.
Microcell fusion
The day before microcell fusion, recipient cells were
trypsinized and counted. A given number of recipient
cells (2 × 104, 2 × 105, 4 × 105, 1 × 106, 2 × 106, or 6 × 106)
were plated in adequate culture vessel (96-well, 24-well,
12-well, 6-well, 60-mm diameter, and 100-mm diameter,
respectively). Donor CHO cells, grown in T-25 flasks
(Nunc), were treated with 0.1 μg/ml colcemid (Gibco) for
72 h to induce micronuclei formation. Flasks were filled
with medium containing 10 μg/ml cytochalasin B (Sigma)
and centrifuged for 1 h at 8,000 rpm (11,899 ×g) in a JLA-
10.5 rotor (Beckman). Pellets containing a crude micro-
cell preparation were recovered and passed through
membranes of 8-, 5-, and 3-μm pore size (Whatman).
Collected microcell preparations were used for fusion
with recipient cells. For PEG fusion, microcells were sus-
pended in DMEM medium (Sigma) containing 50 μg/ml
PHA-P (Difco) and added to the recipient cells. After
incubation at 37°C for 15 min, the medium was dis-
carded. The cells were then exposed to 50% (w/v)
PEG1500 (Roche) for 1 min and washed three times with
serum free medium. On the day following PEG treat-
ment, the cells were trypsinized, sparsely replated, and
cultured for 14 days in medium with 3 μg/ml of Blastici-
din (Funakoshi). For MV fusion, an aliquot of microcells
prepared from CHO4H6.1M was overlaid on recipient
cells and left for 24 h. The cells were then trypsinized,
sparsely replated, and cultured for 14 days in medium
with 3 μg/ml of Blasticidin.
FISH analysis
Metaphase chromosomes were prepared from colcemid-
treated cell cultures by hypotonic treatment with 0.075 M
KCl and methanol/acetate (3:1) fixation. Fluorescence in
situ hybridization was carried out using the alphoid DNA
probe p11-4 labeled with digoxigenin (Roche) [34]. The
digoxigenin signal was detected with an anti-digoxigenin-
rhodamine complex (Roche). The chromosomes were
counterstained with DAPI (Sigma). Photographs were
taken using a CCD camera mounted on a fluorescence
m i c r o s c o p e  ( N i k o n ) .  I m a g e s  w e r e  p r o c e s s e d  u s i n g  t h e
software attached to the microscope.
Flow cytometry analysis
Cells were dispersed by treatment with 0.2% EDTA/PBS,
washed twice with PBS, and resuspended in ice-cold PBS
containing 2% (w/v) BSA at a concentration of 106 cells/Katoh et al. BMC Biotechnology 2010, 10:37
http://www.biomedcentral.com/1472-6750/10/37
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ml. The cells were then incubated for 60 min on ice with a
1:50 final dilution of FITC-labeled anti-CD46 antibody
(clone E4.3; BD Pharmingen), or FITC-labeled isotype
control (clone G155-178; BD Pharmingen). After washing
with BSA/PBS, the cells were analyzed by flow cytometry
using an EPICS ALTRA (Beckman Coulter).
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